60
Participants
Start Date
February 14, 2018
Primary Completion Date
November 25, 2020
Study Completion Date
June 23, 2021
fitusiran
solution for injection; by subcutaneous (SC) injection
Bypassing agents
solution for injection; by intravenous (IV) injection
Investigational Site Number 8801, Taipei
Investigational Site Number 8803, Changhua
Investigational Site Number 2703, Polokwane
Investigational Site Number 6101, Camperdown
Investigational Site Number 2701, Parktown
Investigational Site Number 6104, Clayton
Investigational Site Number 8203, Seoul
Investigational Site Number 4906, Leipzig
Investigational Site Number 2702, Port Elizabeth
Investigational Site Number 0136, Baltimore
Investigational Site Number 3402, Madrid
Investigational Site Number 0115, Jacksonville
Investigational Site Number 0128, Gainesville
Investigational Site Number 0105, Miami
Investigational Site Number 0103, Tampa
Investigational Site Number 9005, Istanbul
Investigational Site Number 9003, Izmir
Investigational Site Number 3904, Padua
Investigational Site Number 8202, Daejeon
Investigational Site Number 3901, Florence
Investigational Site Number 4905, Frankfurt am Main
Investigational Site Number 3303, Lyon
Investigational Site Number 0119, New Orleans
Investigational Site Number 3301, Rouen
Investigational Site Number 8002, Lviv
Investigational Site Number 0117, Phoenix
Investigational Site Number 6003, Kota Kinabalu
Investigational Site Number 0111, Las Vegas
Investigational Site Number 0139, Los Angeles
Investigational Site Number 0137, San Diego
Investigational Site Number 0135, Orange
Investigational Site Number 8604, Beijing
Investigational Site Number 8603, Shanghai
Investigational Site Number 9106, Lucknow
Investigational Site Number 8601, Tianjin
Investigational Site Number 9104, Jaipur
Investigational Site Number 8605, Hangzhou
Investigational Site Number 9103, Pune
Investigational Site Number 9111, Pune
Investigational Site Number 8602, Guangzhou
Investigational Site Number 9102, Bangalore
Investigational Site Number 9105, Vellore
Investigational Site Number 0104, Philadelphia
Investigational Site Number 1102, Montreal
Investigational Site Number 9108, India
Investigational Site Number 8110, Japan
Investigational Site Number 8103, Kita Kyushu-Shi
Investigational Site Number 6004, Malaysia
Investigational Site Number 8204, Seoul
Investigational Site Number 8804, Dawan
Investigational Site Number 8805, Dawan
Investigational Site Number 9006, Turkey
Investigational Site Number 9002, Adana
Investigational Site Number 9004, Akdeniz
Investigational Site Number 9001, Ankara
Investigational Site Number 8003, Kyiv
Investigational Site Number 8001, Kyiv
Investigational Site Number 4407, London
Genzyme, a Sanofi Company
INDUSTRY